CD163 and diffuse large B-cell lymphoma: To determine whether CD163+ macrophages profiles were able to define low‐ and high‐risk populations in our clinical cohort, we evaluated the CD163 protein expression by using immunohistochemistry assay on 85 samples corresponding to DLBCL.